BioSig Technologies, Inc. STEX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.86M-66.2% | $20.32M+83.9% | $11.05M+292% | $2.82M-24.3% | $3.73M+2,525% | ||
| -$11K— | —— | —— | —— | $109K0.0% | ||
| $45.9M-36.2% | $71.9M+380% | $14.99M+400% | $3M-24.7% | $3.99M+927% | ||
| $12K-52.0% | $25K-34.2% | $38K-28.3% | $53K-22.1% | $68K-20.0% | ||
| $69.76M-1.7% | $70.98M+1.6% | $69.89M+19.1% | $58.69M— | —— | ||
| $42.42M-5.0% | $44.64M-1.7% | $45.41M-5.2% | $47.92M+17,982% | $265K-1.5% | ||
| —— | $700K— | —— | —— | —— | ||
| $127.41M+10.2% | $115.65M+0.1% | $115.52M+8.2% | $106.72M— | —— | ||
| $173.32M-7.6% | $187.54M+43.7% | $130.51M+19.0% | $109.72M+2,383% | $4.42M+425% | ||
| —— | $19.7M— | —— | —— | —— | ||
| $3.3M-92.3% | $42.79M-65.9% | $125.6M+11.0% | $113.2M+6,642% | $1.68M-25.8% | ||
| $13.97M-74.2% | $54.22M-60.5% | $137.34M+21.3% | $113.2M+6,642% | $1.68M-25.8% | ||
| 500M0.0% | 500M0.0% | 500M+150% | 200M0.0% | 200M-60.0% | ||
| -$764.81M-6.5% | -$718.12M-144% | -$294.11M-5.6% | -$278.53M-7.9% | -$258.16M-1.1% | ||
| $158.99M+19.4% | $133.19M+2,014% | -$6.96M-92.4% | -$3.62M-239% | $2.61M+269% | ||
| $173.32M-7.6% | $187.54M+43.7% | $130.51M+19.0% | $109.72M+2,383% | $4.42M+425% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are BioSig Technologies, Inc.'s total assets?
- BioSig Technologies, Inc. (STEX) holds $173.3M in total assets, up 3823.0% year over year.
- How much cash does BioSig Technologies, Inc. have?
- BioSig Technologies, Inc. holds $6.9M in cash and equivalents.
- Can BioSig Technologies, Inc. cover its short-term obligations?
- Its current ratio is 13.90 — current assets exceed current liabilities.
- Where does BioSig Technologies, Inc.'s balance sheet data come from?
- Every line is extracted from BioSig Technologies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
